208 related articles for article (PubMed ID: 35577980)
1. TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice.
Hamad SH; Montgomery SA; Simon JM; Bowman BM; Spainhower KB; Murphy RM; Knudsen ES; Fenton SE; Randell SH; Holt JR; Hayes DN; Witkiewicz AK; Oliver TG; Major MB; Weissman BE
Oncogene; 2022 Jun; 41(25):3423-3432. PubMed ID: 35577980
[TBL] [Abstract][Full Text] [Related]
2. A conditional mouse expressing an activating mutation in NRF2 displays hyperplasia of the upper gastrointestinal tract and decreased white adipose tissue.
Bowman BM; Montgomery SA; Schrank TP; Simon JM; Ptacek TS; Tamir TY; Mulvaney KM; Weir SJ; Nguyen TT; Murphy RM; Makowski L; Hayes DN; Chen XL; Randell SH; Weissman BE; Major MB
J Pathol; 2020 Oct; 252(2):125-137. PubMed ID: 32619021
[TBL] [Abstract][Full Text] [Related]
3. NRF2 Activation in Trp53;p16-deficient Mice Drives Oral Squamous Cell Carcinoma.
Hamad SH; Sellers RS; Wamsley N; Zolkind P; Schrank TP; Major MB; Weissman BE
Cancer Res Commun; 2024 Feb; 4(2):487-495. PubMed ID: 38335300
[TBL] [Abstract][Full Text] [Related]
4. Triple marker composed of p16, CD56, and TTF1 shows higher sensitivity than INSM1 for diagnosis of pulmonary small cell carcinoma: proposal for a rational immunohistochemical algorithm for diagnosis of small cell carcinoma in small biopsy and cytology specimens.
Švajdler M; Mezencev R; Šašková B; Ondič O; Mukenšnábl P; Michal M
Hum Pathol; 2019 Mar; 85():58-64. PubMed ID: 30385371
[TBL] [Abstract][Full Text] [Related]
5. NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas.
Meder L; König K; Ozretić L; Schultheis AM; Ueckeroth F; Ade CP; Albus K; Boehm D; Rommerscheidt-Fuss U; Florin A; Buhl T; Hartmann W; Wolf J; Merkelbach-Bruse S; Eilers M; Perner S; Heukamp LC; Buettner R
Int J Cancer; 2016 Feb; 138(4):927-38. PubMed ID: 26340530
[TBL] [Abstract][Full Text] [Related]
6. Rb Tumor Suppressor in Small Cell Lung Cancer: Combined Genomic and IHC Analysis with a Description of a Distinct Rb-Proficient Subset.
Febres-Aldana CA; Chang JC; Ptashkin R; Wang Y; Gedvilaite E; Baine MK; Travis WD; Ventura K; Bodd F; Yu HA; Quintanal-Villalonga A; Lai WV; Egger JV; Offin M; Ladanyi M; Rudin CM; Rekhtman N
Clin Cancer Res; 2022 Nov; 28(21):4702-4713. PubMed ID: 35792876
[TBL] [Abstract][Full Text] [Related]
7. Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities.
Simbolo M; Centonze G; Ali G; Garzone G; Taormina S; Sabella G; Ciaparrone C; Mafficini A; Grillo F; Mangogna A; Volante M; Mastracci L; Fontanini G; Pilotto S; Bria E; Infante M; Capella C; Rolli L; Pastorino U; Milella M; Milione M; Scarpa A
ESMO Open; 2022 Feb; 7(1):100308. PubMed ID: 34952268
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of Rb1, cyclin D1 and p16 immunohistochemistry expression to distinguish lung small-cell carcinoma and large-cell neuroendocrine carcinoma.
Papaxoinis G; Bille A; McLean E; Nonaka D
Histopathology; 2022 Aug; 81(2):205-214. PubMed ID: 35544410
[TBL] [Abstract][Full Text] [Related]
9. The comparative pathology of genetically engineered mouse models for neuroendocrine carcinomas of the lung.
Gazdar AF; Savage TK; Johnson JE; Berns A; Sage J; Linnoila RI; MacPherson D; McFadden DG; Farago A; Jacks T; Travis WD; Brambilla E
J Thorac Oncol; 2015 Apr; 10(4):553-64. PubMed ID: 25675280
[TBL] [Abstract][Full Text] [Related]
10. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
[TBL] [Abstract][Full Text] [Related]
11. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
[TBL] [Abstract][Full Text] [Related]
12. Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance.
Jeong Y; Hoang NT; Lovejoy A; Stehr H; Newman AM; Gentles AJ; Kong W; Truong D; Martin S; Chaudhuri A; Heiser D; Zhou L; Say C; Carter JN; Hiniker SM; Loo BW; West RB; Beachy P; Alizadeh AA; Diehn M
Cancer Discov; 2017 Jan; 7(1):86-101. PubMed ID: 27663899
[TBL] [Abstract][Full Text] [Related]
13. 1,25-Dihydroxyvitamin D exerts an antiaging role by activation of Nrf2-antioxidant signaling and inactivation of p16/p53-senescence signaling.
Chen L; Yang R; Qiao W; Zhang W; Chen J; Mao L; Goltzman D; Miao D
Aging Cell; 2019 Jun; 18(3):e12951. PubMed ID: 30907059
[TBL] [Abstract][Full Text] [Related]
14. Ascl1-induced Wnt11 regulates neuroendocrine differentiation, cell proliferation, and E-cadherin expression in small-cell lung cancer and Wnt11 regulates small-cell lung cancer biology.
Tenjin Y; Kudoh S; Kubota S; Yamada T; Matsuo A; Sato Y; Ichimura T; Kohrogi H; Sashida G; Sakagami T; Ito T
Lab Invest; 2019 Nov; 99(11):1622-1635. PubMed ID: 31231131
[TBL] [Abstract][Full Text] [Related]
15. TRP53 Mutants Drive Neuroendocrine Lung Cancer Through Loss-of-Function Mechanisms with Gain-of-Function Effects on Chemotherapy Response.
Akeno N; Reece AL; Callahan M; Miller AL; Kim RG; He D; Lane A; Moulton JS; Wikenheiser-Brokamp KA
Mol Cancer Ther; 2017 Dec; 16(12):2913-2926. PubMed ID: 28847987
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
[TBL] [Abstract][Full Text] [Related]
17. Molecular genetics of small cell lung carcinoma.
Wistuba II; Gazdar AF; Minna JD
Semin Oncol; 2001 Apr; 28(2 Suppl 4):3-13. PubMed ID: 11479891
[TBL] [Abstract][Full Text] [Related]
18. POU2F3: A Sensitive and Specific Diagnostic Marker for Neuroendocrine-low/negative Small Cell Lung Cancer.
Wang Y; Jin Y; Shen X; Zheng Q; Xue Q; Chen L; Lin Y; Li Y
Am J Surg Pathol; 2023 Sep; 47(9):1059-1066. PubMed ID: 37357936
[TBL] [Abstract][Full Text] [Related]
19. P16 is a useful supplemental diagnostic marker of pulmonary small cell carcinoma in small biopsies and cytology specimens.
Švajdler M; Mezencev R; Ondič O; Šašková B; Mukenšnábl P; Michal M
Ann Diagn Pathol; 2018 Apr; 33():23-29. PubMed ID: 29566943
[TBL] [Abstract][Full Text] [Related]
20. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
